Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336410 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT04336410 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT04336410, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers.
Interventions
- DEVICE CELLECTRA® 2000
- DRUG INO-4800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-04-03 |
| Est. Completion | 2022-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04336410
The ClinicalTrials.gov registry entry for NCT04336410 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CELLECTRA® 2000 is the first listed.
NCT04336410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04336410 about?
NCT04336410 is a clinical study titled "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers.
What is the current status of trial NCT04336410?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2020-04-03. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT04336410?
The interventions under investigation include: CELLECTRA® 2000 (DEVICE), INO-4800 (DRUG).
Who is sponsoring clinical trial NCT04336410?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.